These results are in line with the recent TUXEDO-1 study demonstrating impressive efficacy of T-DXd for HER2+ BC patients with parenchymal brain metastases, and a recent publication by Alder et al. describing a case series of BC LM patients treated with T-DXd [27,28]. The gene discussed is ERBB2; the disease is lymphangioma.